Skip to main content
SpringerLink
Log in

Nutraceuticals and Lipid Management

  • Chapter
  • First Online:
Therapeutic Lipidology

Part of the book series: Contemporary Cardiology ((CONCARD))

Abstract

Scientific data support the effectiveness of reducing total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) in preventing atherosclerotic disease cardiovascular disease (ASCVD) events. Current guidelines suggest the use of innovative nutritional strategies in lipid management based on consumption of nutraceuticals and functional foods. Nutraceuticals are products isolated or purified from foods (generally sold in medicinal forms), while a functional food is similar in appearance to, or may be, a conventional food. Both nutritional components promote health, lead to better well-being, and reduce risk of cardiovascular disease, possibly by affecting plasma lipid levels. The most frequently occurring lipid-lowering substances in nutraceuticals and functional foods are red yeast rice, phytosterols and stanols, omega-3 fatty acids, beta-glucan, berberine, soy, lupin and its products, (poly)phenols as well as antioxidants, which can be used alone or in combination. Specific guidelines for their use in clinical practice are still needed. Nutraceuticals may be used to achieve LDL-C targets, especially in cases of statin intolerance, while their efficacy in patients with chronic kidney disease requires further investigation. However, lipid-lowering therapy cannot be replaced by nutraceuticals, but their use might help to optimize it, providing incremental capacity to reduce residual CV risk. Despite being freely available for purchase, nutraceuticals and functional foods should be used for the control of lipids level under a physician’s direction. The mechanisms by which nutraceuticals exert efficacy are an area of active worldwide investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Authors/Task Force M, Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European atherosclerosis society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;253:281–344.

    Article  CAS  Google Scholar 

  2. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint Task Force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33:1635–701.

    Article  CAS  PubMed  Google Scholar 

  3. Poli A, Visioli F. Pharmacology of nutraceuticals with lipid lowering properties. High Blood Press Cardiovasc Prev. 2019;26:113–8.

    Article  CAS  PubMed  Google Scholar 

  4. Daliu P, Santini A, Novellino E. From pharmaceuticals to nutraceuticals: bridging disease prevention and management. Expert Rev Clin Pharmacol. 2019;12:1–7.

    Article  CAS  PubMed  Google Scholar 

  5. Doyon M, Labrecque J. Functional foods: a conceptual definition. Br Food J. 2008;110:1133–49.

    Article  Google Scholar 

  6. Chen CH, Yang JC, Uang YS, Lin CJ. Improved dissolution rate and oral bioavailability of lovastatin in red yeast rice products. Int J Pharm. 2013;444:18–24.

    Article  CAS  PubMed  Google Scholar 

  7. Li Y, Jiang L, Jia Z, Xin W, Yang S, Yang Q, et al. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. PLoS One. 2014;9:e98611.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Ye P, Lu ZL, Du BM, Chen Z, Wu YF, Yu XH, et al. Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from the China Coronary Secondary Prevention Study. J Am Geriatr Soc. 2007;55:1015–22.

    Article  PubMed  Google Scholar 

  9. Fogacci F, Banach M, Mikhailidis DP, Bruckert E, Toth PP, Watts GF, et al. Safety of red yeast rice supplementation: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2019;143:1–16.

    Article  CAS  PubMed  Google Scholar 

  10. Marangoni F, Poli A. Phytosterols and cardiovascular health. Pharmacol Res. 2010;61:193–9.

    Article  CAS  PubMed  Google Scholar 

  11. Ras RT, Geleijnse JM, Trautwein EA. LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled studies. Br J Nutr. 2014;112:214–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Trautwein EA, Koppenol WP, de Jong A, Hiemstra H, Vermeer MA, Noakes M, et al. Plant sterols lower LDL-cholesterol and triglycerides in dyslipidemic individuals with or at risk of developing type 2 diabetes; a randomized, double-blind, placebo-controlled study. Nutr Diabetes. 2018;8:30.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Poli A, Barbagallo CM, Cicero AFG, Corsini A, Manzato E, Trimarco B, et al. Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper. Pharmacol Res. 2018;134:51–60.

    Article  CAS  PubMed  Google Scholar 

  14. Rocha VZ, Ras RT, Gagliardi AC, Mangili LC, Trautwein EA, Santos RD. Effects of phytosterols on markers of inflammation: a systematic review and meta-analysis. Atherosclerosis. 2016;248:76–83.

    Article  CAS  PubMed  Google Scholar 

  15. Gylling H, Plat J, Turley S, Ginsberg HN, Ellegard L, Jessup W, et al. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis. 2014;232:346–60.

    Article  CAS  PubMed  Google Scholar 

  16. Ho HV, Sievenpiper JL, Zurbau A, Blanco Mejia S, Jovanovski E, Au-Yeung F, et al. The effect of oat beta-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: a systematic review and meta-analysis of randomised-controlled trials. Br J Nutr. 2016;116:1369–82.

    Article  CAS  PubMed  Google Scholar 

  17. Cicero AFG, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, et al. Lipid-lowering nutraceuticals in clinical practice: position paper from an international lipid expert panel. Nutr Rev. 2017;75:731–67.

    Article  PubMed  Google Scholar 

  18. Behera SS, Ray RC. Konjac glucomannan, a promising polysaccharide of Amorphophallus konjac K. Koch in health care. Int J Biol Macromol. 2016;92:942–56.

    Article  CAS  PubMed  Google Scholar 

  19. Sood N, Baker WL, Coleman CI. Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. Am J Clin Nutr. 2008;88:1167–75.

    Article  CAS  PubMed  Google Scholar 

  20. Ho HVT, Jovanovski E, Zurbau A, Blanco Mejia S, Sievenpiper JL, Au-Yeung F, et al. A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets non-HDL cholesterol and apolipoprotein B. Am J Clin Nutr. 2017;105:1239–47.

    Article  CAS  PubMed  Google Scholar 

  21. Anderson JW. Dietary fibre, complex carbohydrate and coronary artery disease. Can J Cardiol. 1995;11 Suppl G:55G–62G.

    Google Scholar 

  22. Wei ZH, Wang H, Chen XY, Wang BS, Rong ZX, Wang BS, et al. Time- and dose-dependent effect of psyllium on serum lipids in mild-to-moderate hypercholesterolemia: a meta-analysis of controlled clinical trials. Eur J Clin Nutr. 2009;63:821–7.

    Article  CAS  PubMed  Google Scholar 

  23. Moraru C, Mincea MM, Frandes M, Timar B, Ostafe V. A meta-analysis on randomised controlled clinical trials evaluating the effect of the dietary supplement chitosan on weight loss, lipid parameters and blood pressure. Medicina (Kaunas). 2018;54:109.

    Article  Google Scholar 

  24. Dong H, Zhao Y, Zhao L, Lu F. The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials. Planta Med. 2013;79:437–46.

    Article  CAS  PubMed  Google Scholar 

  25. Pirillo A, Catapano AL. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: from in vitro evidence to clinical studies. Atherosclerosis. 2015;243:449–61.

    Article  CAS  PubMed  Google Scholar 

  26. Caliceti C, Franco P, Spinozzi S, Roda A, Cicero AF. Berberine: new insights from pharmacological aspects to clinical evidences in the management of metabolic disorders. Curr Med Chem. 2016;23:1460–76.

    Article  CAS  PubMed  Google Scholar 

  27. Zhu L, Zhang D, Zhu H, Zhu J, Weng S, Dong L, et al. Berberine treatment increases Akkermansia in the gut and improves high-fat diet-induced atherosclerosis in Apoe(−/−) mice. Atherosclerosis. 2018;268:117–26.

    Article  CAS  PubMed  Google Scholar 

  28. Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019;25:1096–103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Eslick GD, Howe PR, Smith C, Priest R, Bensoussan A. Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol. 2009;136:4–16.

    Article  PubMed  Google Scholar 

  30. Hartweg J, Farmer AJ, Perera R, Holman RR, Neil HA. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. Diabetologia. 2007;50:1593–602.

    Article  CAS  PubMed  Google Scholar 

  31. Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep. 2011;13:474–83.

    Article  CAS  PubMed  Google Scholar 

  32. Hooper L, Thompson RL, Harrison RA, Summerbell CD, Moore H, Worthington HV, et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev. 2004;(4):CD003177.

    Google Scholar 

  33. Berge K, Musa-Veloso K, Harwood M, Hoem N, Burri L. Krill oil supplementation lowers serum triglycerides without increasing low-density lipoprotein cholesterol in adults with borderline high or high triglyceride levels. Nutr Res. 2014;34:126–33.

    Article  CAS  PubMed  Google Scholar 

  34. Nikolic D, Katsiki N, Montalto G, Isenovic ER, Mikhailidis DP, Rizzo M. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients. 2013;5:928–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Ulven SM, Kirkhus B, Lamglait A, Basu S, Elind E, Haider T, et al. Metabolic effects of krill oil are essentially similar to those of fish oil but at lower dose of EPA and DHA, in healthy volunteers. Lipids. 2011;46:37–46.

    Article  CAS  PubMed  Google Scholar 

  36. Weintraub H. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options. Atherosclerosis. 2013;230:381–9.

    Article  CAS  PubMed  Google Scholar 

  37. Alexander DD, Miller PE, Van Elswyk ME, Kuratko CN, Bylsma LC. A meta-analysis of randomized controlled trials and prospective cohort studies of eicosapentaenoic and docosahexaenoic long-chain omega-3 fatty acids and coronary heart disease risk. Mayo Clin Proc. 2017;92:15–29.

    Article  CAS  PubMed  Google Scholar 

  38. Kromhout D, Giltay EJ, Geleijnse JM, Alpha Omega Trial G. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363:2015–26.

    Article  CAS  PubMed  Google Scholar 

  39. Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019;380:23–32.

    Article  CAS  PubMed  Google Scholar 

  40. Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018;11:CD003177.

    PubMed  Google Scholar 

  41. Bhatt DL, Steg PG, Miller M. Cardiovascular risk reduction with Icosapent ethyl. Reply N Engl J Med. 2019;380:1678.

    PubMed  Google Scholar 

  42. Mori TA, Bao DQ, Burke V, Puddey IB, Watts GF, Beilin LJ. Dietary fish as a major component of a weight-loss diet: effect on serum lipids, glucose, and insulin metabolism in overweight hypertensive subjects. Am J Clin Nutr. 1999;70:817–25.

    Article  CAS  PubMed  Google Scholar 

  43. Mori TA, Bao DQ, Burke V, Puddey IB, Beilin LJ. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension. 1999;34:253–60.

    Article  CAS  PubMed  Google Scholar 

  44. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223–30.

    Article  PubMed  CAS  Google Scholar 

  45. Hunter PM, Hegele RA. Functional foods and dietary supplements for the management of dyslipidaemia. Nat Rev Endocrinol. 2017;13:278–88.

    Article  CAS  PubMed  Google Scholar 

  46. Silagy C, Neil A. Garlic as a lipid lowering agent--a meta-analysis. J R Coll Physicians Lond. 1994;28:39–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Stevinson C, Pittler MH, Ernst E. Garlic for treating hypercholesterolemia. A meta-analysis of randomized clinical trials. Ann Intern Med. 2000;133:420–9.

    Article  CAS  PubMed  Google Scholar 

  48. van Nielen M, Feskens EJ, Rietman A, Siebelink E, Mensink M. Partly replacing meat protein with soy protein alters insulin resistance and blood lipids in postmenopausal women with abdominal obesity. J Nutr. 2014;144:1423–9.

    Article  PubMed  CAS  Google Scholar 

  49. Simental-Mendia LE, Gotto AM Jr, Atkin SL, Banach M, Pirro M, Sahebkar A. Effect of soy isoflavone supplementation on plasma lipoprotein(a) concentrations: a meta-analysis. J Clin Lipidol. 2018;12:16–24.

    Article  PubMed  Google Scholar 

  50. Lou D, Li Y, Yan G, Bu J, Wang H. Soy consumption with risk of coronary heart disease and stroke: a meta-analysis of observational studies. Neuroepidemiology. 2016;46:242–52.

    Article  PubMed  Google Scholar 

  51. Giglio RV, Patti AM, Nikolic D, Li Volti G, Al-Rasadi K, Katsiki N, et al. The effect of bergamot on dyslipidemia. Phytomedicine. 2016;23:1175–81.

    Article  CAS  PubMed  Google Scholar 

  52. Toth PP, Patti AM, Nikolic D, Giglio RV, Castellino G, Biancucci T, et al. Bergamot reduces plasma lipids, atherogenic small dense LDL, and subclinical atherosclerosis in subjects with moderate hypercholesterolemia: a 6 months prospective study. Front Pharmacol. 2015;6:299.

    PubMed  Google Scholar 

  53. Gong J, Qin X, Yuan F, Hu M, Chen G, Fang K, et al. Efficacy and safety of sugarcane policosanol on dyslipidemia: a meta-analysis of randomized controlled trials. Mol Nutr Food Res. 2018;62 https://doi.org/10.1002/mnfr.201700280.

  54. Gadelha C, Bezerra AN. Effects of probiotics on the lipid profile: systematic review. J Vasc Bras. 2019;18:e20180124.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Wang L, Guo MJ, Gao Q, Yang JF, Yang L, Pang XL, et al. The effects of probiotics on total cholesterol: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018;97:e9679.

    Article  CAS  Google Scholar 

  56. Mo R, Zhang X, Yang Y. Effect of probiotics on lipid profiles in hypercholesterolaemic adults: a meta-analysis of randomized controlled trials. Med Clin (Barc). 2019;152:473–81.

    Article  Google Scholar 

  57. Dibaba DT. Effect of vitamin D supplementation on serum lipid profiles: a systematic review and meta-analysis. Nutr Rev. 2019;77:890–902.

    Article  PubMed  Google Scholar 

  58. Giustina A, Adler RA, Binkley N, Bollerslev J, Bouillon R, Dawson-Hughes B, et al. Consensus statement from 2(nd) International Conference on Controversies in Vitamin D. Rev Endocr Metab Disord. 2020;21:89–116.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Ware WR. The JUPITER lipid lowering trial and vitamin D: is there a connection? Dermatoendocrinol. 2010;2:50–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Momtazi AA, Banach M, Pirro M, Katsiki N, Sahebkar A. Regulation of PCSK9 by nutraceuticals. Pharmacol Res. 2017;120:157–69.

    Article  CAS  PubMed  Google Scholar 

  61. Fogacci F, Grassi D, Rizzo M, Cicero AFG. Metabolic effect of berberine-silymarin association: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Phytother Res. 2019;33:862–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Cicero AFG, Fogacci F, Bove M, Veronesi M, Rizzo M, Giovannini M, et al. Short-term effects of a combined nutraceutical on lipid level, fatty liver biomarkers, hemodynamic parameters, and estimated cardiovascular disease risk: a double-blind, placebo-controlled randomized clinical trial. Adv Ther. 2017;34:1966–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Barrios V, Escobar C, Cicero AF, Burke D, Fasching P, Banach M, et al. A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: review of the clinical evidence. Atheroscler Suppl. 2017;24:1–15.

    Article  PubMed  Google Scholar 

  64. Iwamoto T, Hosoda K, Hirano R, Kurata H, Matsumoto A, Miki W, et al. Inhibition of low-density lipoprotein oxidation by astaxanthin. J Atheroscler Thromb. 2000;7:216–22.

    Article  CAS  PubMed  Google Scholar 

  65. Ursoniu S, Sahebkar A, Serban MC, Banach M. Lipid profile and glucose changes after supplementation with astaxanthin: a systematic review and meta-analysis of randomized controlled trials. Arch Med Sci. 2015;11:253–66.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Hernandez-Camacho JD, Bernier M, Lopez-Lluch G, Navas P. Coenzyme Q10 supplementation in aging and disease. Front Physiol. 2018;9:44.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Cicero AFG, Colletti A, von Haehling S, Vinereanu D, Bielecka-Dabrowa A, Sahebkar A, et al. Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP). Nutr Res Rev. 2020:1–25. https://doi.org/10.1017/S0954422420000049.

  68. Lopez-Lluch G, Del Pozo-Cruz J, Sanchez-Cuesta A, Cortes-Rodriguez AB, Navas P. Bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization. Nutrition. 2019;57:133–40.

    Article  CAS  PubMed  Google Scholar 

  69. Pirro M, Mannarino MR, Bianconi V, Simental-Mendia LE, Bagaglia F, Mannarino E, et al. The effects of a nutraceutical combination on plasma lipids and glucose: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2016;110:76–88.

    Article  CAS  PubMed  Google Scholar 

  70. Sahebkar A, Simental-Mendia LE, Stefanutti C, Pirro M. Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: a systematic review and meta-analysis. Pharmacol Res. 2016;105:198–209.

    Article  CAS  PubMed  Google Scholar 

  71. Littarru GP, Tiano L. Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol Biotechnol. 2007;37:31–7.

    Article  CAS  PubMed  Google Scholar 

  72. Pulido-Moran M, Moreno-Fernandez J, Ramirez-Tortosa C, Ramirez-Tortosa M. Curcumin and health. Molecules. 2016;21:264.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  73. Qin S, Huang L, Gong J, Shen S, Huang J, Ren H, et al. Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials. Nutr J. 2017;16:68.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  74. Panahi Y, Khalili N, Sahebi E, Namazi S, Reiner Z, Majeed M, et al. Curcuminoids modify lipid profile in type 2 diabetes mellitus: a randomized controlled trial. Complement Ther Med. 2017;33:1–5.

    Article  PubMed  Google Scholar 

  75. Salehi B, Del Prado-Audelo ML, Cortes H, Leyva-Gomez G, Stojanovic-Radic Z, Singh YD, et al. Therapeutic applications of curcumin nanomedicine formulations in cardiovascular diseases. J Clin Med. 2020;9 https://doi.org/10.3390/jcm9030746.

  76. Patti AM, Al-Rasadi K, Katsiki N, Banerjee Y, Nikolic D, Vanella L, et al. Effect of a natural supplement containing Curcuma Longa, Guggul, and chlorogenic acid in patients with metabolic syndrome. Angiology. 2015;66:856–61.

    Article  CAS  PubMed  Google Scholar 

  77. Onakpoya I, Spencer E, Heneghan C, Thompson M. The effect of green tea on blood pressure and lipid profile: a systematic review and meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014;24:823–36.

    Article  CAS  PubMed  Google Scholar 

  78. Khalesi S, Sun J, Buys N, Jamshidi A, Nikbakht-Nasrabadi E, Khosravi-Boroujeni H. Green tea catechins and blood pressure: a systematic review and meta-analysis of randomised controlled trials. Eur J Nutr. 2014;53:1299–311.

    Article  CAS  PubMed  Google Scholar 

  79. Basu A, Sanchez K, Leyva MJ, Wu M, Betts NM, Aston CE, et al. Green tea supplementation affects body weight, lipids, and lipid peroxidation in obese subjects with metabolic syndrome. J Am Coll Nutr. 2010;29:31–40.

    Article  CAS  PubMed  Google Scholar 

  80. Chen X, He K, Wei C, Yang W, Geng Z. Green tea powder decreased egg weight through increased liver lipoprotein lipase and decreased plasma total cholesterol in an indigenous chicken breed. Animals (Basel). 2020;10:370.

    Article  Google Scholar 

  81. Erba D, Riso P, Bordoni A, Foti P, Biagi PL, Testolin G. Effectiveness of moderate green tea consumption on antioxidative status and plasma lipid profile in humans. J Nutr Biochem. 2005;16:144–9.

    Article  CAS  PubMed  Google Scholar 

  82. Giovinazzo G, Ingrosso I, Paradiso A, De Gara L, Santino A. Resveratrol biosynthesis: plant metabolic engineering for nutritional improvement of food. Plant Foods Hum Nutr. 2012;67:191–9.

    Article  CAS  PubMed  Google Scholar 

  83. Salehi B, Mishra AP, Nigam M, Sener B, Kilic M, Sharifi-Rad M, et al. Resveratrol: a double-edged sword in health benefits. Biomedicine. 2018;6:91.

    CAS  Google Scholar 

  84. Akbari M, Tamtaji OR, Lankarani KB, Tabrizi R, Dadgostar E, Haghighat N, et al. The effects of resveratrol on lipid profiles and liver enzymes in patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis. 2020;19:25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Simental-Mendia LE, Guerrero-Romero F. Effect of resveratrol supplementation on lipid profile in subjects with dyslipidemia: a randomized double-blind, placebo-controlled trial. Nutrition. 2019;58:7–10.

    Article  CAS  PubMed  Google Scholar 

  86. Kiskova T, Kassayova M. Resveratrol action on lipid metabolism in cancer. Int J Mol Sci. 2019;20:2704.

    Article  CAS  PubMed Central  Google Scholar 

  87. Castellino G, Nikolic D, Magan-Fernandez A, Malfa GA, Chianetta R, Patti AM, et al. Altilix((R)) supplement containing chlorogenic acid and luteolin improved hepatic and cardiometabolic parameters in subjects with metabolic syndrome: a 6 month randomized, double-blind, placebo-controlled study. Nutrients. 2019;11:2580.

    Article  CAS  PubMed Central  Google Scholar 

  88. Sahebkar A, Pirro M, Banach M, Mikhailidis DP, Atkin SL, Cicero AFG. Lipid-lowering activity of artichoke extracts: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2018;58:2549–56.

    Article  CAS  PubMed  Google Scholar 

  89. Dominguez Diaz L, Fernandez-Ruiz V, Camara M. The frontier between nutrition and pharma: the international regulatory framework of functional foods, food supplements and nutraceuticals. Crit Rev Food Sci Nutr. 2020;60:1738–46.

    Article  CAS  PubMed  Google Scholar 

  90. Katsiki N, Mikhailidis DP, Banach M. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. Expert Opin Pharmacother. 2019;20:2007–17.

    Article  CAS  PubMed  Google Scholar 

  91. Banach M, Patti AM, Giglio RV, Cicero AFG, Atanasov AG, Bajraktari G, et al. The role of nutraceuticals in statin intolerant patients. J Am Coll Cardiol. 2018;72:96–118.

    Article  PubMed  Google Scholar 

  92. Rossman MJ, LaRocca TJ, Martens CR, Seals DR. Healthy lifestyle-based approaches for successful vascular aging. J Appl Physiol (1985). 2018;125:1888–900.

    Article  CAS  Google Scholar 

  93. Kruse NT. Nutraceuticals as a potential adjunct therapy toward improving vascular health in CKD. Am J Physiol Regul Integr Comp Physiol. 2019;317:R719–R32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999–3058.

    Article  PubMed  Google Scholar 

  95. Lee SM, An WS. Cardioprotective effects of omega −3 PUFAs in chronic kidney disease. Biomed Res Int. 2013;2013:712949.

    PubMed  PubMed Central  Google Scholar 

  96. Saglimbene VM, Wong G, van Zwieten A, Palmer SC, Ruospo M, Natale P, et al. Effects of omega-3 polyunsaturated fatty acid intake in patients with chronic kidney disease: systematic review and meta-analysis of randomized controlled trials. Clin Nutr. 2020;39:358–68.

    Article  CAS  PubMed  Google Scholar 

  97. Friedman AN, Yu Z, Tabbey R, Denski C, Tamez H, Wenger J, et al. Inverse relationship between long-chain n-3 fatty acids and risk of sudden cardiac death in patients starting hemodialysis. Kidney Int. 2013;83:1130–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Hoogeveen EK, Geleijnse JM, Kromhout D, Stijnen T, Gemen EF, Kusters R, et al. Effect of omega-3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clin J Am Soc Nephrol. 2014;9:1676–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Nikolic D, Banach M, Chianetta R, Luzzu LM, Pantea Stoian A, Diaconu CC, et al. An overview of statin-induced myopathy and perspectives for the future. Expert Opin Drug Saf. 2020;19:601–15.

    Article  CAS  PubMed  Google Scholar 

  100. Katsiki N, Mikhailidis DP, Bajraktari G, Miserez AR, Cicero AFG, Bruckert E, et al. Statin therapy in athletes and patients performing regular intense exercise – position paper from the International Lipid Expert Panel (ILEP). Pharmacol Res. 2020;155:104719.

    Article  CAS  PubMed  Google Scholar 

  101. Ference BA. Mendelian randomization studies: using naturally randomized genetic data to fill evidence gaps. Curr Opin Lipidol. 2015;26:566–71.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 2nd Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece

    Alexandros G. Sachinidis

  2. Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy

    Dragana Nikolic & Manfredi Rizzo

  3. Department of Diabetes, Nutrition and Metabolic Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

    Anca Pantea Stoian

  4. Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Peter P. Toth

  5. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of South Carolina, Palermo, Italy

    Manfredi Rizzo

Authors
  1. Alexandros G. Sachinidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dragana Nikolic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anca Pantea Stoian
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter P. Toth
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Manfredi Rizzo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manfredi Rizzo .

Editor information

Editors and Affiliations

  1. The University of Chicago Pritzker School of Medicine, Chicago, IL, USA

    Michael H. Davidson

  2. Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins Univerity School of Medicine, Baltimore, MD, USA

    Peter P. Toth

  3. Department of Applied Health Science, Indiana University School of Public Health, Bloomington, IN, USA

    Kevin C. Maki

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sachinidis, A.G., Nikolic, D., Stoian, A.P., Toth, P.P., Rizzo, M. (2021). Nutraceuticals and Lipid Management. In: Davidson, M.H., Toth, P.P., Maki, K.C. (eds) Therapeutic Lipidology. Contemporary Cardiology. Humana, Cham. https://doi.org/10.1007/978-3-030-56514-5_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-56514-5_10

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-56513-8

  • Online ISBN: 978-3-030-56514-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation